Vosoritide therapy in children with achondroplasia aged 3−59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial

Ravi Savarirayan*, William R. Wilcox, Paul Harmatz, John Phillips, Lynda E. Polgreen, Louise Tofts, Keiichi Ozono, Paul Arundel, Melita Irving, Carlos A. Bacino, Donald Basel, Michael B. Bober, Joel Charrow, Hiroshi Mochizuki, Yumiko Kotani, Howard M. Saal, Clare Army, George Jeha, Yulan Qi, Lynn HanElena Fisheleva, Alice Huntsman-Labed, Jonathan Day

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Fingerprint

Dive into the research topics of 'Vosoritide therapy in children with achondroplasia aged 3−59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science